Université Pierre Et Marie Curie (Paris 6)

Institut Curie

Institute Curie

Sorbonne Université

Harmonic Pharma

Didier Decaudin

Angelita Rebollo Garcia

Fariba Nemati

Jeronimo Bravo Sicilia

Jesus Maria Fominaya Gutierrez

Violeta Isabel Perez-Nueno

Michel Souchet

Arnaud Sinan Karaboga

The present invention relates to a new class of cephalosporin derivatives of formula (I), notably having CXCR4 receptor antagonist effect, useful as a therapeutic agent for treating cancer, in particular for treating breast cancer, lung cancer and uveal melanoma. The invention further relates to a pharmaceutical composition comprising a compound of formula (I) and an additional antitumor drug for treating cancer.

Derivatives of cephalosporin for treating cancer

The invention provides an in vitro method for determining the likelihood for a patient affected with a tumor to respond to a treatment with a pro-apoptotic peptide able to disrupt interaction between caspase 9 and PP2A, which method comprises determining expression level of at least each of VIM, MK167, TCF7L2, NEK2, BIRC5, MCL1, and PLK1 genes, in a biological sample of said patient.

Method of predicting a response to an anti-tumor treatment

The invention relates to an isolated peptide inhibitor of the interaction between the TEAD and YAP or TAZ proteins and a derived chimeric peptide linked to a cell-penetrating peptide. These peptides which have a cytotoxic activity are useful, in particular for the treatment of hyperproliferative disorders such as cancer.

Peptide inhibitors of TEAD/YAP-TAZ interaction

A vector that includes a cell-penetrating peptide linked to a therapeutic agent. The therapeutic agent can be a cytotoxic agent, an anti-viral agent, an anti-bacterial agent, or an anti-parasitic agent.

Cell-penetrating peptides

A chimeric peptide construct having a cell penetrating peptide linked to a pro-apoptotic peptide. The construct can be used for treating a tumor in combination with an anti-tumor agent. Also disclosed is a method for treating a tumor with the chimeric peptide construct and a chemotherapeutic agent.

Anti-tumor adjuvant therapy

A cell-penetrating peptide is described. Also described is a pro-apoptotic agent including the cell-penetrating peptide and a pro-apoptotic peptide linked thereto. The pro-apoptotic agent is useful for inhibition of in vitro cell proliferation and for treatment of tumors.

Growing community of inventors

Verrieres le Buisson, France

Didier Decaudin